RxDoctor Payments Data

Scott Heilmann

Family · Panama City Beach, FLNPI 1164875894

Payments from drug & device makers

$11,712in general payments, 2019–2025

Across 657 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$875
  • Novo Nordisk$841
  • Merck$721
  • Johnson & Johnson$653
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$11,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,712 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$182,109
Medicare patients
479
Services billed
2,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$135,334
MounjaroTirzepatide73$89,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$61,978
JanuviaSitagliptin Phosphate59$61,328
TrulicityDulaglutide32$51,805
RexultiBrexpiprazole35$44,558
JardianceEmpagliflozin46$44,324
MyrbetriqMirabegron65$35,398
FarxigaDapagliflozin Propanediol35$28,383
OzempicSemaglutide14$25,146
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$23,332
EntrestoSacubitril/Valsartan17$21,422
XareltoRivaroxaban26$21,325
LinzessLinaclotide23$17,140
Memantine Hcl271$11,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$875$140,883105 claims
PfizerEliquis$436$135,334208 claims
GSKTrelegy Ellipta$615$61,97852 claims
MerckJanuvia$721$61,32859 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,191$51,71553 claims
Boehringer IngelheimJardiance, Tradjenta$145$50,31758 claims
Otsuka America Pharmaceutical, Inc.Rexulti$328$44,55835 claims
Astellas Pharma US IncMyrbetriq$21$35,39865 claims
Novo NordiskOzempic$841$25,14614 claims
NovartisEntresto$268$21,42217 claims
Johnson & JohnsonXarelto$653$21,32526 claims
AbbVieLinzess$1,663$17,14023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Panama City Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →